TY - JOUR
T1 - The promising role of autologous and allogeneic mesenchymal stromal cells in managing knee osteoarthritis. What is beyond Mesenchymal stromal cells?
AU - Pandey, Vivek
AU - Madi, Sandesh
AU - Gupta, Pawan
N1 - © 2022 Delhi Orthopedic Association. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Mesenchymal stromal cells (MSCs) express a wide range of properties anticipated to be beneficial for treating genetic, mechanical, and age-related degeneration in diseases such as osteoarthritis (OA). Although contemporary conservative management of OA is successful in many patients with mild-moderate OA, it often fails to improve symptoms in many patients who are not a candidate for any surgical management. Further, existing conservative treatment strategies do not prevent the progression of the disease and therefore fail to provide a long-term pain-free life. On the other hand, tremendous progress has been taking place in the exciting field of regenerative medicine involving MSCs (autologous and allogeneic), with promising translation taking place from basic science to the bedside. In this review, we comprehensively discuss the potential role of MSCs in treating OA, both autologous and off-the-shelf, allogeneic stem cells. Further, newer therapies are in the offing to treat OA, such as exosomes and growth factors.
AB - Mesenchymal stromal cells (MSCs) express a wide range of properties anticipated to be beneficial for treating genetic, mechanical, and age-related degeneration in diseases such as osteoarthritis (OA). Although contemporary conservative management of OA is successful in many patients with mild-moderate OA, it often fails to improve symptoms in many patients who are not a candidate for any surgical management. Further, existing conservative treatment strategies do not prevent the progression of the disease and therefore fail to provide a long-term pain-free life. On the other hand, tremendous progress has been taking place in the exciting field of regenerative medicine involving MSCs (autologous and allogeneic), with promising translation taking place from basic science to the bedside. In this review, we comprehensively discuss the potential role of MSCs in treating OA, both autologous and off-the-shelf, allogeneic stem cells. Further, newer therapies are in the offing to treat OA, such as exosomes and growth factors.
UR - http://www.scopus.com/inward/record.url?scp=85124574334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124574334&partnerID=8YFLogxK
U2 - 10.1016/j.jcot.2022.101804
DO - 10.1016/j.jcot.2022.101804
M3 - Review article
C2 - 35242531
AN - SCOPUS:85124574334
SN - 0976-5662
VL - 26
SP - 101804
JO - Journal of Clinical Orthopaedics and Trauma
JF - Journal of Clinical Orthopaedics and Trauma
M1 - 101804
ER -